NEUROCRINE BIOSCIENCES, INC. financials

  1. Home
  2. Financials
  3. NBIX
NBIX CIK 0000914475

Source: EDGAR filings · Built 2026-06-02T03:38:09Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 748.70M 557.20M 361.60M 322.90M 233.10M 217.60M
EBITDA 649.20M 597.60M 272.20M 264.60M 113.40M 171.60M
Working Capital 1.78B 1.22B 952.20M 915.80M 727.00M 829.70M
Net Debt -241.70M 262.70M 209.30M 17.40M 116.10M 235.50M
Gross Margin 98.18% 98.56% 97.90% 98.44% 98.74% 99.03%
Operating Margin 21.64% 24.22% 13.30% 16.73% 9.04% 15.58%
Net Margin 16.73% 14.49% 13.23% 10.38% 7.90% 38.94%
Return on Equity (ROE) 14.71% 13.18% 11.19% 9.05% 6.52% 36.17%
Return on Assets (ROA) 10.33% 9.18% 7.68% 6.52% 4.32% 23.48%
Current Ratio 3.39× 3.40× 2.45× 2.70× 3.96× 5.45×
Debt-to-Equity 0.14× 0.19× 0.21× 0.16× 0.33× 0.38×
Effective Tax Rate 32.15% 29.77% 24.81% 27.77% 11.64% -281.72%
Cash Conversion Ratio 1.64× 1.74× 1.56× 2.20× 2.86× 0.56×
Accruals Ratio -0.07× -0.07× -0.04× -0.08× -0.08× 0.10×
SBC % of Revenue 7.62% 8.30% 10.30% 11.63% 11.84% 9.56%
CapEx Coverage 23.02× 15.59× 13.78× 20.57× 10.96× 20.96×
Free Cash Flow Per Share $7.30 $5.37 $3.58 $3.26 $2.38 $2.22

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 30.37× 41.49× 53.34× 76.56× 92.58× 23.04×
P/FCF 19.42× 25.40× 36.80× 36.58× 35.77× 43.08×
FCF Yield 5.15% 3.94% 2.72% 2.73% 2.80% 2.32%
EV / EBITDA 21.50× 23.14× 48.55× 43.63× 72.30× 53.60×
P/S 4.96× 5.76× 6.89× 7.74× 7.13× 8.57×
P/B 4.36× 5.24× 5.83× 6.75× 5.88× 7.96×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 2.86B 2.36B 1.89B 1.49B 1.13B 1.05B
Cost of Goods and Services Sold 52.10M 34.00M 39.70M 23.20M 14.30M 10.10M
Selling, General and Administrative Expense 1.16B 1.01B 887.60M 752.70M 583.30M 433.30M
Operating Expenses — — — — 1.03B 882.90M
Operating Income (Loss) 619.10M 570.50M 250.90M 249.00M 102.50M 163.00M
Income Tax Expense (Benefit) 226.80M 144.70M 82.40M 59.40M 11.80M -300.60M
Net Income (Loss) Attributable to Parent 478.60M 341.30M 249.70M 154.50M 89.60M 407.30M
Earnings Per Share, Basic $4.81 $3.40 $2.56 $1.61 $0.95 $4.38
Weighted Average Number of Shares Outstanding, Basic 99.50M 100.40M 97.70M 95.80M 94.60M 93.10M
Earnings Per Share, Diluted $4.67 $3.29 $2.47 $1.56 $0.92 $4.16
Weighted Average Number of Shares Outstanding, Diluted 102.50M 103.70M 101.00M 98.90M 97.90M 97.80M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 713.00M 233.00M 251.10M 262.90M 340.80M 187.10M
Assets, Current 2.52B 1.72B 1.61B 1.45B 972.80M 1.02B
Assets 4.63B 3.72B 3.25B 2.37B 2.07B 1.73B
Liabilities, Current 743.40M 507.70M 654.80M 537.70M 245.80M 186.50M
Liabilities 1.38B 1.13B 1.02B 660.90M 698.50M 608.50M
Stockholders' Equity Attributable to Parent 3.25B 2.59B 2.23B 1.71B 1.37B 1.13B
Common Stock, Shares, Outstanding 100.10M 99.40M 98.70M 96.50M 94.90M 93.50M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 782.70M 595.40M 389.90M 339.40M 256.50M 228.50M
Payments to Acquire Property, Plant, and Equipment 34.00M 38.20M 28.30M 16.50M 23.40M 10.90M
Net Cash Provided by (Used in) Investing Activities -264.40M -126.80M -467.10M -177.10M -130.20M 4.10M
Payments for Repurchase of Common Stock 167.70M 300.00M 0 0 — —
Net Cash Provided by (Used in) Financing Activities -38.30M -486.70M 65.30M -234.30M 27.40M -157.80M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NBIX CIK 0000914475), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

LFUS

LITTELFUSE INC /DE

SUI

SUN COMMUNITIES, INC

CHE

CHEMED CORPORATION